Florbetapir F 18 amyloid PET and 36-month cognitive decline

a prospective multicenter study

AV45-A11 Study Group

Research output: Contribution to journalArticle

Abstract

This study was designed to evaluate whether subjects with amyloid beta (Aβ) pathology, detected using florbetapir positron emission tomorgraphy (PET), demonstrated greater cognitive decline than subjects without Aβ pathology. Sixty-nine cognitively normal (CN) controls, 52 with recently diagnosed mild cognitive impairment (MCI) and 31 with probable Alzheimer's disease (AD) dementia were included in the study. PET images obtained in these subjects were visually rated as positive (Aβ+) or negative (Aβ-), blind to diagnosis. Fourteen percent (10/69) of CN, 37% (19/52) of MCI and 68% (21/31) of AD were Aβ+. The primary outcome was change in ADAS-Cog score in MCI subjects after 36 months; however, additional outcomes included change on measures of cognition, function and diagnostic status. Aβ+ MCI subjects demonstrated greater worsening compared with Aβ- subjects on the ADAS-Cog over 36 months (5.66±1.47 vs -0.71±1.09, P=0.0014) as well as on the mini-mental state exam (MMSE), digit symbol substitution(DSS) test, and a verbal fluency test (P

Original languageEnglish (US)
Pages (from-to)1044-1051
Number of pages8
JournalMolecular Psychiatry
Volume19
Issue number9
DOIs
StatePublished - Sep 11 2014

Fingerprint

Amyloid
Multicenter Studies
Prospective Studies
Electrons
Alzheimer Disease
Pathology
Cognition
florbetapir
Cognitive Dysfunction

Keywords

  • alzheimer's disease
  • amyloid
  • cognitive decline
  • florbetapir
  • MCI
  • PET

ASJC Scopus subject areas

  • Molecular Biology
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience
  • Medicine(all)

Cite this

Florbetapir F 18 amyloid PET and 36-month cognitive decline : a prospective multicenter study. / AV45-A11 Study Group.

In: Molecular Psychiatry, Vol. 19, No. 9, 11.09.2014, p. 1044-1051.

Research output: Contribution to journalArticle

@article{252645341c264bdabde13830d67df017,
title = "Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study",
abstract = "This study was designed to evaluate whether subjects with amyloid beta (Aβ) pathology, detected using florbetapir positron emission tomorgraphy (PET), demonstrated greater cognitive decline than subjects without Aβ pathology. Sixty-nine cognitively normal (CN) controls, 52 with recently diagnosed mild cognitive impairment (MCI) and 31 with probable Alzheimer's disease (AD) dementia were included in the study. PET images obtained in these subjects were visually rated as positive (Aβ+) or negative (Aβ-), blind to diagnosis. Fourteen percent (10/69) of CN, 37{\%} (19/52) of MCI and 68{\%} (21/31) of AD were Aβ+. The primary outcome was change in ADAS-Cog score in MCI subjects after 36 months; however, additional outcomes included change on measures of cognition, function and diagnostic status. Aβ+ MCI subjects demonstrated greater worsening compared with Aβ- subjects on the ADAS-Cog over 36 months (5.66±1.47 vs -0.71±1.09, P=0.0014) as well as on the mini-mental state exam (MMSE), digit symbol substitution(DSS) test, and a verbal fluency test (P",
keywords = "alzheimer's disease, amyloid, cognitive decline, florbetapir, MCI, PET",
author = "{AV45-A11 Study Group} and Doraiswamy, {P. Murali} and Sperling, {R. A.} and K. Johnson and Reiman, {Eric M.} and Wong, {T. Z.} and Sabbagh, {M. N.} and Sadowsky, {Carl H.} and Fleisher, {A. S.} and A. Carpenter and Joshi, {A. D.} and M. Lu and M. Grundman and Mintun, {M. A.} and Skovronsky, {D. M.} and Pontecorvo, {M. J.} and Ranjan Duara and Marwan Sabbagh and Ahern, {Geoffrey Lawrence} and Holub, {Richard F.} and Farmer, {Mildred V.} and Safirstein, {Beth Emmie} and Gustavo Alva and Longmire, {Crystal F.} and George Jewell and Johnson, {Keith A.} and Ron Korn and Wendt, {Jeanette K.} and Wong, {Dean Foster} and Coleman, {R. Edward} and Michael Devous and Danna Jennings and Weiner, {Michael W.} and Murphy, {Cynthia A.} and Kovnat, {Karel D.} and Williamson, {Jeff D.}",
year = "2014",
month = "9",
day = "11",
doi = "10.1038/mp.2014.9",
language = "English (US)",
volume = "19",
pages = "1044--1051",
journal = "Molecular Psychiatry",
issn = "1359-4184",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Florbetapir F 18 amyloid PET and 36-month cognitive decline

T2 - a prospective multicenter study

AU - AV45-A11 Study Group

AU - Doraiswamy, P. Murali

AU - Sperling, R. A.

AU - Johnson, K.

AU - Reiman, Eric M.

AU - Wong, T. Z.

AU - Sabbagh, M. N.

AU - Sadowsky, Carl H.

AU - Fleisher, A. S.

AU - Carpenter, A.

AU - Joshi, A. D.

AU - Lu, M.

AU - Grundman, M.

AU - Mintun, M. A.

AU - Skovronsky, D. M.

AU - Pontecorvo, M. J.

AU - Duara, Ranjan

AU - Sabbagh, Marwan

AU - Ahern, Geoffrey Lawrence

AU - Holub, Richard F.

AU - Farmer, Mildred V.

AU - Safirstein, Beth Emmie

AU - Alva, Gustavo

AU - Longmire, Crystal F.

AU - Jewell, George

AU - Johnson, Keith A.

AU - Korn, Ron

AU - Wendt, Jeanette K.

AU - Wong, Dean Foster

AU - Coleman, R. Edward

AU - Devous, Michael

AU - Jennings, Danna

AU - Weiner, Michael W.

AU - Murphy, Cynthia A.

AU - Kovnat, Karel D.

AU - Williamson, Jeff D.

PY - 2014/9/11

Y1 - 2014/9/11

N2 - This study was designed to evaluate whether subjects with amyloid beta (Aβ) pathology, detected using florbetapir positron emission tomorgraphy (PET), demonstrated greater cognitive decline than subjects without Aβ pathology. Sixty-nine cognitively normal (CN) controls, 52 with recently diagnosed mild cognitive impairment (MCI) and 31 with probable Alzheimer's disease (AD) dementia were included in the study. PET images obtained in these subjects were visually rated as positive (Aβ+) or negative (Aβ-), blind to diagnosis. Fourteen percent (10/69) of CN, 37% (19/52) of MCI and 68% (21/31) of AD were Aβ+. The primary outcome was change in ADAS-Cog score in MCI subjects after 36 months; however, additional outcomes included change on measures of cognition, function and diagnostic status. Aβ+ MCI subjects demonstrated greater worsening compared with Aβ- subjects on the ADAS-Cog over 36 months (5.66±1.47 vs -0.71±1.09, P=0.0014) as well as on the mini-mental state exam (MMSE), digit symbol substitution(DSS) test, and a verbal fluency test (P

AB - This study was designed to evaluate whether subjects with amyloid beta (Aβ) pathology, detected using florbetapir positron emission tomorgraphy (PET), demonstrated greater cognitive decline than subjects without Aβ pathology. Sixty-nine cognitively normal (CN) controls, 52 with recently diagnosed mild cognitive impairment (MCI) and 31 with probable Alzheimer's disease (AD) dementia were included in the study. PET images obtained in these subjects were visually rated as positive (Aβ+) or negative (Aβ-), blind to diagnosis. Fourteen percent (10/69) of CN, 37% (19/52) of MCI and 68% (21/31) of AD were Aβ+. The primary outcome was change in ADAS-Cog score in MCI subjects after 36 months; however, additional outcomes included change on measures of cognition, function and diagnostic status. Aβ+ MCI subjects demonstrated greater worsening compared with Aβ- subjects on the ADAS-Cog over 36 months (5.66±1.47 vs -0.71±1.09, P=0.0014) as well as on the mini-mental state exam (MMSE), digit symbol substitution(DSS) test, and a verbal fluency test (P

KW - alzheimer's disease

KW - amyloid

KW - cognitive decline

KW - florbetapir

KW - MCI

KW - PET

UR - http://www.scopus.com/inward/record.url?scp=84905557091&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905557091&partnerID=8YFLogxK

U2 - 10.1038/mp.2014.9

DO - 10.1038/mp.2014.9

M3 - Article

VL - 19

SP - 1044

EP - 1051

JO - Molecular Psychiatry

JF - Molecular Psychiatry

SN - 1359-4184

IS - 9

ER -